Patient Advocacy Leader | 26 Years in Myeloma Education & Support | Care Partner | Community Builder | Connecting People, Advancing Care & Inspiring Hope 💙
Prospect, CT
Joined December 2012
- Tweets7K
- Following1K
- Followers2.5K
- Likes8.1K
Robin Tuohy retweeted
"Why not replace stem cell transplant entirely with CAR-T therapy?" Dr. Joe breaks it down. Drop your questions below and bookmark this video for later.
#AskTheIMF #mmsm @Bethfaiman @jmikhaelmd
Robin Tuohy retweeted
For sure one of the coolest things I’ve ever gotten to be part of
A super impressive project, featuring interviews with everyone from the CEOs to the leading outside voices on AI risk. I’m in it too :)
Go watch on March 27!
Robin Tuohy retweeted
#KansasCity: Connect with the myeloma community, build your support network, ask the experts your questions, find support in your community, and for FREE on March 28, 2026! Will we see you there? Save your seat before spots are gone: mmsm.link/3Ns8Dox
#mmsm
Robin Tuohy retweeted
Traditional PET/CT can miss up to 30% of slow-growing #myeloma lesions. IMMunoPET uses antibodies labeled with zirconium-89 to specifically target myeloma. revealing both previously undetectable and additional disease sites. #mmsm #ASH25 @DrOlaLandgren
youtu.be/HP5ObhJ4nkw?si=wVRe…
Robin Tuohy retweeted
A great news for drug approval in myeloma. Will fast forward patient access to new drugs! A success of I2TEAMM efforts @VincentRK @NoopurRajeMD @IMFmyeloma
@SagarLonialMD #mmsm
Source: U.S. Food and Drug Administration share.google/A1uZjJoEuFNOSqu…
Robin Tuohy retweeted
New options for people with hard-to-treat myeloma outside the bone (extramedullary) mean more hope and the potential for longer, better lives. Research is leading the way.
@jmikhaelmd
#ASH25 #IMFASH25 #ASKTHEIMF
Robin Tuohy retweeted
Fascinating abstract examining whether ALC, a routinely measured lab, can serve as a predictor of delayed neurotoxicity following CAR-T therapy in MM. Nice to see research looking to improve CAR-T safety for us patients! #IMFASH25 #ASH25 #myeloma #mmsm
meetings-api.hematology.org/…
Robin Tuohy retweeted
Original Article: Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (MajesTEC-3 phase 3 trial) nej.md/4431DUD
#ASH25 | @ASH_hematology
ALT The Kaplan–Meier estimate of overall survival at 36 months among the patients in the teclistamab–daratumumab group and the DPd or DVd group
Robin Tuohy retweeted
Stay tuned for the final set of algorithms for relapsed refractory myeloma, Third line (Second relapse) or later.
#ASH25
OK here it is. Finally.
My #ASH25 algorithm for Relapsed Myeloma: First Relapse. Discussed with @YiLinMDPhD @myelomaMD
Give comments. I’m willing to adjust it based on your insights.
Robin Tuohy retweeted
#ASH25 MajesTEC-3 will transform #MMsm care even more than CAR-T for many 🌏 pts in near future.
But to shout (again) from rooftop: to do tec-dara safely, use primary IVIG/SCIG prophylaxis!
Excellent suppl fig in @NEJM illustrating why OS curves crossed and how they fixed it.
Robin Tuohy retweeted
Here is how dramatically this trial has changed approach to first relapse.
OK here it is. Finally.
My #ASH25 algorithm for Relapsed Myeloma: First Relapse. Discussed with @YiLinMDPhD @myelomaMD
Give comments. I’m willing to adjust it based on your insights.
Robin Tuohy retweeted
Just out in @NEJM
Majestec-3 trial. Tec-Dara in relapsed myeloma. #ASH25 @End_myeloma @mvmateos
Link: nejm.org/doi/full/10.1056/NE…
More in thread
Robin Tuohy retweeted
From a patient perspective, this is beyond exciting. Bringing more hope for a cure. #ASH25 #IMFASH25 #mmsm @IMFmyeloma @jmikhaelmd
In-vivo BCMA CAR-T first in human trial. 3 patients all achieving MRD negativity.
This could be revolutionary - no need for lymphodepletion chemo, no complicated cell manufacturing process and better memory T cell phenotype.
Looking forward to more data esp safety
#ASH25
Robin Tuohy retweeted
Presented at #ASH25:
In drug-resistant extramedullary myeloma, dual treatment with talquetamab and teclistamab produced a response in 79% of patients, and 12-month overall survival was 74%; however, grade 3 or 4 adverse events were common. Full RedirecTT-1 phase 1b–2 study results: nej.md/4pKghIv
@ASH_hematology
Robin Tuohy retweeted
Monoclonal Gammopathy of Renal Significance (MGRS) - Landau @MSKCancerCenter #mmsm #nephroonc #onconeph Summary
Robin Tuohy retweeted
Most patients, the default is a quadruplet.
Either Dara or Isa can be used as anti CD38 depending on access and availability
Prefer DaraVRd or IsaVRd rather than KRd based regimens
For standard risk early or delayed transplant depending on patient preference, response to induction, and tolerability of induction.
For standard risk doublet maintenance if MRD positive and/or Anti CD38 naive
We are awaiting results of trials to limit duration of maintenance, for both Len and Anti CD 38. Stay tuned.
#ASH25
Robin Tuohy retweeted
#ASH25 excellent by @LaurenMerzMD et al:
Proof positive that Duffy null (largely Black or Arab) have more high-grade neutropenia with len #MMsm but 0% NTP fevers sans ASCT.
That’s right - ZERO NTP fevers (FN) here in DETERMINATION. Don’t dose reduce len here for ANC alone!
Robin Tuohy retweeted
POEMS syndrome can be challenging to diagnose and treat. @ADispenzieri the world expert in this condition speaking at #ASH25 on this condition.
@jmikhaelmd chairing this scientific session.
Robin Tuohy retweeted
Just out: Effective treatment of extra medullary relapsed myeloma with teclistamab plus talquetamab (Tec-Tal). RedirecTT-1 @NEJM #ASH25
@myelomaMD @szusmani @mvmateos
80% response rate.
60% PFS at 12 months.
Link in thread
